

BIOGEN IDEC INC.
Form 3
August 21, 2007

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Clancy Paul J		(Month/Day/Year)	BIOGEN IDEC INC. [BIIB]	
(Last)	(First)	(Middle)	08/13/2007	
14 CAMBRIDGE CENTER			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
CAMBRIDGE,Â MAÂ 02142			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other	<input checked="" type="checkbox"/> Form filed by One Reporting Person
			(give title below) (specify below)	<input type="checkbox"/> Form filed by More than One Reporting Person
			CFO	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	24,395	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Title	Amount or Number of		

Edgar Filing: BIOGEN IDEC INC. - Form 3

				Shares		(I) (Instr. 5)	
Stock Option (right to buy)	Â (1)	03/05/2011	Common Stock	28,750	\$ 58.99	D	Â
Stock Option (right to buy)	Â (2)	12/14/2011	Common Stock	4,761	\$ 49.03	D	Â
Stock Option (right to buy)	Â (3)	12/06/2012	Common Stock	10,005	\$ 37.45	D	Â
Stock Option (right to buy)	Â (4)	02/06/2014	Common Stock	13,000	\$ 43.5	D	Â
Stock Option (right to buy)	Â (5)	02/17/2015	Common Stock	8,400	\$ 67.57	D	Â
Stock Option (right to buy)	Â (6)	02/06/2016	Common Stock	10,990	\$ 44.24	D	Â
Stock Option (right to buy)	Â (7)	08/01/2016	Common Stock	6,000	\$ 41.03	D	Â
Stock Option (right to buy)	Â (8)	02/12/2017	Common Stock	18,100	\$ 49.31	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Clancy Paul J 14 CAMBRIDGE CENTER CAMBRIDGE, MA 02142	Â	Â	Â CFO	Â

Signatures

Robert A. Licht, Attorney in Fact for Paul J. Clancy
08/21/2007

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The stock option became exercisable in five (5) equal annual installments, commencing one year after the grant date of 3/5/2001
- (2) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/14/01.
- (3) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/06/02.
- (4) The stock option becomes exercisable in four(4) equal annual installments, commencing one year after the grant date of 02/06/04.
- (5) The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/17/05.
- (6) The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/06/06.
- (7) The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 8/01/06.
- (8) The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/12/07.

Edgar Filing: BIOGEN IDEC INC. - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.